Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Summary

COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver disease are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. Therefore, early inoculation of SARS-CoV-2 vaccine in patients with liver disease is an important protective measure. However, information on the effectiveness and safety of the COVID-19 vaccine for liver disease remains to be determined. This muilticentre study (CHESS2101) aims to study the effectiveness and safety of the COVID-19 vaccination for patients with liver disease.

Conditions

• COVID-19
• Liver Disease
• Vaccine Reaction

Sponsors & Collaborators

• LanZhou University

  collaborator OTHER

• Huashan Hospital

  collaborator OTHER

• The Sixth People's Hospital of Shenyang City

  collaborator UNKNOWN

• Xingtai City People's Hospital

  collaborator UNKNOWN

• Jinchang Central Hospital

  collaborator UNKNOWN

• Baoding People's Hospital

  collaborator UNKNOWN

• The Third People's Hospital of Zhenjiang City

  collaborator UNKNOWN

• Shanxi Bethune Hospital

  collaborator OTHER

• Wuhan Jinyintan Hospital

  collaborator UNKNOWN

• Jincheng People's Hospital

  collaborator OTHER

• The Third People's Hospital of Tibet Autonomous Region

  collaborator UNKNOWN

• People's Hospital of Ningxia Hui Autonomous Region

  collaborator OTHER

• Fuling Central Hospital of Chongqing City

  collaborator OTHER

• Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region

  collaborator UNKNOWN

• The Central Hospital of Lishui City

  collaborator OTHER

• The Third People's Hospital of Linfen City

  collaborator UNKNOWN

• Yibin First People's Hospital

  collaborator UNKNOWN

• Jingzhou Central Hospital

  collaborator OTHER

• Wuxi Fifth People's Hospital

  collaborator UNKNOWN

• Qingyang People's Hospital

  collaborator UNKNOWN

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Beilun Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Henan Provincial People's Hospital

  collaborator OTHER

• Qingdao Sixth People's Hospital

  collaborator UNKNOWN

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Beijing YouAn Hospital

  collaborator OTHER

• The First People's Hospital of Taicang

  collaborator UNKNOWN

• The Third People's Hospital of Taiyuan

  collaborator OTHER

• Tianjin Second People's Hospital

  collaborator OTHER

• Tianjin Third Central Hospital

  collaborator OTHER

• Qishan Hospital of Yantai City

  collaborator UNKNOWN

• Affiliated Hospital of Yunnan University

  collaborator OTHER

• The First People's Hospital of Yunnan

  collaborator OTHER

• The Fourth Affiliated Hospital of Zhejiang University

  collaborator UNKNOWN

• Third Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Hepatopancreatobiliary Surgery Institute of Gansu Province

  lead OTHER

Principal Investigators

• Xiaolong Qi, MD · LanZhou University

• Wenhong Zhang, MD · Huashan Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-11

Primary Completion

2022-01-01

Completion

2022-05-01

Countries

• China

Study Locations